A detailed history of Teacher Retirement System Of Texas transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Teacher Retirement System Of Texas holds 12,542 shares of RCUS stock, worth $199,543. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,542
Previous 10,971 14.32%
Holding current value
$199,543
Previous $167,000 14.37%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$13.69 - $18.01 $21,506 - $28,293
1,571 Added 14.32%
12,542 $191,000
Q2 2024

Aug 09, 2024

BUY
$14.59 - $18.48 $2,057 - $2,605
141 Added 1.3%
10,971 $167,000
Q1 2024

May 06, 2024

SELL
$14.83 - $20.18 $4,819 - $6,558
-325 Reduced 2.91%
10,830 $204,000
Q4 2023

Feb 07, 2024

SELL
$13.43 - $19.63 $31,439 - $45,953
-2,341 Reduced 17.35%
11,155 $213,000
Q3 2023

Oct 31, 2023

BUY
$17.62 - $23.54 $28,421 - $37,970
1,613 Added 13.57%
13,496 $242,000
Q2 2023

Jul 19, 2023

SELL
$16.97 - $22.03 $25,455 - $33,045
-1,500 Reduced 11.21%
11,883 $241,000
Q1 2023

May 12, 2023

BUY
$15.96 - $23.15 $13,661 - $19,816
856 Added 6.83%
13,383 $244,000
Q4 2022

Feb 10, 2023

SELL
$19.7 - $35.71 $31,480 - $57,064
-1,598 Reduced 11.31%
12,527 $259,000
Q3 2022

Nov 03, 2022

BUY
$23.23 - $30.07 $328,123 - $424,738
14,125 New
14,125 $370,000
Q2 2022

Aug 09, 2022

SELL
$17.23 - $37.73 $136,771 - $299,500
-7,938 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$28.92 - $41.83 $17,062 - $24,679
590 Added 8.03%
7,938 $251,000
Q4 2021

Feb 10, 2022

BUY
$31.38 - $48.47 $33,262 - $51,378
1,060 Added 16.86%
7,348 $297,000
Q3 2021

Nov 09, 2021

BUY
$26.93 - $37.68 $169,335 - $236,931
6,288 New
6,288 $219,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.15B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Teacher Retirement System Of Texas Portfolio

Follow Teacher Retirement System Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teacher Retirement System Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on Teacher Retirement System Of Texas with notifications on news.